Effects of Intramuscular Injection of Autologous Immunoglobulin on Clinical Severity and Serum IgE Concentration in Patients with Atopic Dermatitis

Abstract

Background/Objective: The management of patients with atopic dermatitis (AD) is often difficult for both patients and physicians. We hypothesized that repeated intramuscular injections of autologous immunoglobulin can induce clinical improvement in patients with AD by correcting immune dysfunction. Methods: Seventeen adult patients with severe AD were treated by intramuscular injection of 50 mg autologous immunoglobulin (mainly IgG with a purity ≥97%) twice a week for 4 weeks. The standardized clinical severity scoring system for AD (SCORAD) value and serum IgE concentration were measured at baseline and at 4, 8, and 12 weeks. Results: SCORAD values and serum IgE concentrations significantly decreased at 4, 8, and 12 weeks compared to baseline (p < 0.05). No significant side effects were observed. Conclusions: Repeated intramuscular injections of autologous immunoglobulin significantly decreased the clinical severity and serum IgE concentration in patients with severe AD. Further studies are required to evaluate the clinical significance of these findings.

Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis

“…This result suggested that immune dysfunction and hypersensitivity reaction play key roles in the pathogenesis of AD and could be the critical therapeutic targets for AD 3. Further development of a new therapeutic modality is required to change the long-term clinical course of AD 356…”

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

“…Treatment of atopic dermatitis with intramuscular immunoglobulin has been described in a pilot study of 17 adults . A regimen of 50 mg of autologous immunoglobulin twice weekly for 4 weeks was associated with a significant decrease in SCORAD and followed by remission for at least 8 weeks, with no evident side effects.…”

Alternative Immunomodulatory and Disease-Modifying Treatment for Atopic Dermatitis: Autologous Total Immunoglobulin G

“…In 2015, the authors first demonstrated the efficacy of AIGT, which was a pilot study of 17 adult patients with severe AD. 5 In that study, AIGT given twice a week for 4 weeks significantly decreased clinical severity and serum immunoglobulin (Ig) E concentration in all 17 patients. In addition, clinical and laboratory improvements by AIGT lasted for 8 weeks even after its cessation.…”